We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 106% below its sector, cheaper than its peers on earnings.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save PKY.AX and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
